PHARM.AS AMS
Pharming Group N.V.
1W: -6.2%
1M: -10.6%
3M: -30.4%
YTD: -36.5%
1Y: -30.4%
3Y: -25.0%
5Y: +4.7%
€0.87 ($0.98)
-0.02 (-1.76%)
Weekly Expected Move ±4.6%
€1
€1
€1
€1
€1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$426M
+10.0% ▲
5Y CAGR: +0.3%
Total Liabilities
$190M
+9.9% ▲
5Y CAGR: -4.2%
Shareholders Equity
$277M
+29.4% ▲
5Y CAGR: +8.6%
Cash & Investments
$153M
-5.5% ▼
5Y CAGR: -5.7%
Total Debt
$99M
-9.1% ▼
5Y CAGR: -9.5%
Net Debt
-$26M
-146.6% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $192M | $207M | $62M | $53M | $124M |
| Short-Term Investments | $0 | $0 | $152M | $109M | $29M |
| Cash & ST Investments | $192M | $207M | $213M | $162M | $153M |
| Net Receivables | $16M | $20M | $43M | $48M | $47M |
| Inventory | $27M | $42M | $57M | $54M | $55M |
| Other Current Assets | $227K | $213K | $11M | $0 | $853 |
| Total Current Assets | $249M | $278M | $316M | $269M | $255M |
| Property, Plant & Equip. | $33M | $39M | $33M | $23M | $20M |
| Goodwill & Intangibles | $84M | $75M | $71M | $59M | $115M |
| Long-Term Investments | $10M | $10M | $9M | $4M | $8M |
| Other Non-Current Assets | -$303K | $1M | $3M | $850K | $80K |
| Total Non-Current Assets | $148M | $148M | $147M | $118M | $171M |
| Total Assets | $397M | $426M | $463M | $387M | $426M |
| — Liabilities — | |||||
| Accounts Payable | $5M | $6M | $15M | $10M | $90M |
| Short-Term Debt | $2K | $2M | $2M | $4M | $5M |
| Deferred Revenue | -$44K | -$56K | $0 | $0 | $0 |
| Other Current Liabilities | $3M | $2M | $8M | $42M | -$282K |
| Total Current Liabilities | $47M | $60M | $78M | $74M | $99M |
| Long-Term Debt | $122M | $123M | $137M | $75M | $79M |
| Other Non-Current Liab. | $17M | $9M | $0 | $0 | $0 |
| Total Non-Current Liabilities | $157M | $161M | $166M | $101M | $91M |
| Total Liabilities | $204M | $221M | $244M | $173M | $190M |
| — Equity — | |||||
| Common Stock | $7M | $8M | $7M | $8M | $8M |
| Retained Earnings | -$269M | -$256M | -$265M | -$265M | -$273M |
| Accumulated OCI | $2M | -$9M | -$2M | -$202K | $29M |
| Total Stockholders Equity | $193M | $205M | $219M | $214M | $277M |
| Total Liabilities & Equity | $397M | $426M | $463M | $387M | $426M |
| — Key Metrics — | |||||
| Total Debt | $162M | $167M | $172M | $108M | $99M |
| Net Debt | -$30M | -$41M | $110M | $55M | -$26M |
| Total Investments | $10M | $10M | $162M | $113M | $37M |